| Pantothenate and CoA biosynthesis |
1.49 |
6.90e-1 |
14/21 (66.67%) |
BCAT1;ENPP1;AASDHPPT;...
|
| RNA degradation |
1.48 |
5.79e-1 |
53/79 (67.09%) |
LSM5;CNOT4;ENO2;...
|
| Purine metabolism |
1.47 |
4.90e-1 |
102/129 (79.07%) |
PDE4B;GUCY1A1;ENPP1;...
|
| Spliceosome |
1.42 |
6.18e-1 |
101/150 (67.33%) |
LSM5;PRPF4;HSPA8;...
|
| Complement and coagulation cascades |
1.42 |
5.40e-1 |
76/85 (89.41%) |
CLU;TFPI;ITGB2;...
|
| Sulfur metabolism |
1.39 |
5.91e-1 |
9/10 (90%) |
PAPSS2;SQOR;SELENBP1;...
|
| African trypanosomiasis |
1.38 |
5.80e-1 |
32/37 (86.49%) |
GNAQ;SELE;IDO1;...
|
| Ferroptosis |
1.34 |
6.85e-1 |
36/41 (87.8%) |
CP;TF;STEAP3;...
|
| Caffeine metabolism |
1.31 |
7.54e-1 |
5/6 (83.33%) |
CYP1A2;NAT1;NAT2;...
|
| Hedgehog signaling pathway |
1.31 |
7.22e-1 |
43/56 (76.79%) |
GAS1;SCUBE2;SPOP;...
|
| RNA transport |
1.29 |
7.56e-1 |
128/186 (68.82%) |
NUP93;XPO1;EIF2S3;...
|
| Gap junction |
1.29 |
7.03e-1 |
72/88 (81.82%) |
GUCY1A1;GNAQ;GUCY1B1;...
|
| Neutrophil extracellular trap formation |
1.28 |
6.66e-1 |
101/189 (53.44%) |
NCF2;ITGB2;FGG;...
|
| DNA replication |
1.26 |
7.27e-1 |
34/36 (94.44%) |
FEN1;PRIM1;RNASEH1;...
|
| Tryptophan metabolism |
1.25 |
7.38e-1 |
35/42 (83.33%) |
KYNU;ALDH7A1;IDO1;...
|
| Biosynthesis of unsaturated fatty acids |
1.24 |
7.00e-1 |
21/27 (77.78%) |
FADS1;FADS2;ACOX1;...
|
| Retinol metabolism |
1.24 |
6.94e-1 |
41/68 (60.29%) |
CYP26B1;ALDH1A2;HSD17B6;...
|
| Non-homologous end-joining |
1.20 |
7.60e-1 |
11/13 (84.62%) |
MRE11;FEN1;PRKDC
|
| MicroRNAs in cancer |
1.19 |
7.55e-1 |
146/310 (47.1%) |
CD44;CDKN1B;ZEB2;...
|
| One carbon pool by folate |
1.16 |
7.56e-1 |
15/20 (75%) |
MTHFD1;GART;MTR;...
|
| Transcriptional misregulation in cancer |
1.16 |
7.37e-1 |
158/192 (82.29%) |
CDKN1B;PROM1;BCL11B;...
|
| Amoebiasis |
1.15 |
7.42e-1 |
99/102 (97.06%) |
GNAQ;ITGB2;TGFB2;...
|
| Staphylococcus aureus infection |
1.15 |
7.33e-1 |
72/95 (75.79%) |
DEFB1;ITGB2;FGG;...
|
| PI3K-Akt signaling pathway |
1.14 |
7.13e-1 |
317/354 (89.55%) |
SPP1;CDKN1B;PPP2R5E;...
|
| Fc gamma R-mediated phagocytosis |
1.14 |
7.19e-1 |
79/97 (81.44%) |
ASAP2;CRK;HCK;...
|
| FoxO signaling pathway |
1.14 |
7.00e-1 |
118/131 (90.08%) |
CDKN1B;PLK2;SGK1;...
|
| Melanogenesis |
1.13 |
6.85e-1 |
74/101 (73.27%) |
TYRP1;GNAQ;DCT;...
|
| Platelet activation |
1.13 |
6.73e-1 |
106/124 (85.48%) |
TBXA2R;GUCY1A1;GNAQ;...
|
| Parkinson disease |
1.04 |
7.66e-1 |
176/249 (70.68%) |
TUBB;UCHL1;SLC6A3;...
|
| Proteasome |
1.04 |
7.58e-1 |
44/46 (95.65%) |
PSMA7;PSMD11;PSMB7;...
|
| Intestinal immune network for IgA production |
-1.34 |
3.59e-1 |
38/48 (79.17%) |
AICDA;LTBR;HLA-DQB1;...
|
| Hepatitis C |
-1.34 |
3.55e-1 |
139/157 (88.54%) |
MAVS;OAS3;PPARA;...
|
| Lysosome |
-1.35 |
3.48e-1 |
115/128 (89.84%) |
SLC11A2;CTSL;GLB1;...
|
| Breast cancer |
-1.36 |
3.51e-1 |
119/147 (80.95%) |
HES1;CTNNB1;JUN;...
|
| Epithelial cell signaling in Helicobacter pylori infect... |
-1.36 |
3.57e-1 |
62/70 (88.57%) |
ATP6V0E1;MET;JAM2;...
|
| Glioma |
-1.40 |
3.55e-1 |
67/75 (89.33%) |
PLCG2;PIK3CD;ARAF;...
|
| Basal cell carcinoma |
-1.41 |
3.30e-1 |
41/63 (65.08%) |
GADD45A;BAX;GADD45G;...
|
| Retrograde endocannabinoid signaling |
-1.41 |
3.33e-1 |
118/148 (79.73%) |
ITPR2;MGLL;NDUFS4;...
|
| Oxidative phosphorylation |
-1.42 |
3.30e-1 |
93/133 (69.92%) |
NDUFS1;COX17;ATP6V0E1;...
|
| Mitophagy |
-1.44 |
2.87e-1 |
56/68 (82.35%) |
BCL2L1;ULK1;BCL2L13;...
|
| NF-kappa B signaling pathway |
-1.45 |
2.93e-1 |
90/104 (86.54%) |
IL1B;GADD45B;CSNK2A1;...
|
| NOD-like receptor signaling pathway |
-1.45 |
3.01e-1 |
145/181 (80.11%) |
IRF9;TNFAIP3;TRAF2;...
|
| Notch signaling pathway |
-1.47 |
2.79e-1 |
49/59 (83.05%) |
JAG2;LFNG;APH1B;...
|
| Th1 and Th2 cell differentiation |
-1.48 |
2.67e-1 |
80/92 (86.96%) |
STAT1;JAG1;IL2;...
|
| Glycerophospholipid metabolism |
-1.48 |
2.79e-1 |
71/98 (72.45%) |
PLA2G5;CDS1;PCYT2;...
|
| Vibrio cholerae infection |
-1.48 |
2.97e-1 |
44/50 (88%) |
ATP6V0E1;PDIA4;ATP6V1H;...
|
| Thyroid cancer |
-1.50 |
2.70e-1 |
36/37 (97.3%) |
HRAS;TPM3;GADD45A;...
|
| Synaptic vesicle cycle |
-1.51 |
2.73e-1 |
63/78 (80.77%) |
CLTCL1;DNM1;ATP6V0E1;...
|
| Graft-versus-host disease |
-1.52 |
2.84e-1 |
32/42 (76.19%) |
HLA-DRA;HLA-C;HLA-A;...
|
| Rheumatoid arthritis |
-1.52 |
3.06e-1 |
78/93 (83.87%) |
MMP3;IL6;CXCL12;...
|
| Non-alcoholic fatty liver disease |
-1.54 |
2.73e-1 |
126/155 (81.29%) |
MAPK11;MAPK9;MAP3K5;...
|
| Melanoma |
-1.55 |
2.93e-1 |
68/72 (94.44%) |
PIK3CD;ARAF;HRAS;...
|
| Protein processing in endoplasmic reticulum |
-1.56 |
3.06e-1 |
127/171 (74.27%) |
MAN1A1;LMAN2;EDEM1;...
|
| Ribosome |
-1.61 |
2.45e-1 |
113/158 (71.52%) |
RPS29;RPL27A;RPL7A;...
|
| Bladder cancer |
-1.65 |
1.92e-1 |
40/41 (97.56%) |
RPS6KA5;MMP1;ARAF;...
|
| B cell receptor signaling pathway |
-1.68 |
1.81e-1 |
71/81 (87.65%) |
MALT1;JUN;CHUK;...
|
| Type I diabetes mellitus |
-1.69 |
1.76e-1 |
38/43 (88.37%) |
HLA-DRA;HLA-C;HLA-A;...
|
| Amino sugar and nucleotide sugar metabolism |
-1.75 |
1.10e-1 |
38/48 (79.17%) |
GALT;GCK;CYB5R1;...
|
| Protein digestion and absorption |
-1.76 |
1.37e-1 |
78/103 (75.73%) |
ATP1B3;SLC3A1;CTRL;...
|
| Other glycan degradation |
-1.80 |
1.30e-1 |
13/18 (72.22%) |
NEU1;MAN2C1;GLB1;...
|
